^
    almost2years
    A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=15, Completed, Lupin Ltd. | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • NRAS mutation
    |
    LNP3794
    almost2years
    A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS]) (clinicaltrials.gov)
    P1, N=8, Terminated, Boehringer Ingelheim | Completed --> Terminated; Sponsor decision
    Preclinical • Trial termination • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12 • KRAS G13 • KRAS A146 • KRAS Q61 • KRAS A59 • KRAS K117 • KRAS exon 4 mutation
    |
    LNP3794 • BI 1701963
    2years
    A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS]) (clinicaltrials.gov)
    P1, N=8, Completed, Boehringer Ingelheim | Terminated --> Completed
    Trial completion
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12 • KRAS G13 • KRAS A146 • KRAS Q61 • KRAS A59 • KRAS K117 • KRAS exon 4 mutation
    |
    LNP3794 • BI 1701963
    2years
    A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive) (clinicaltrials.gov)
    P1, N=15, Completed, Boehringer Ingelheim | Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> Oct 2022
    Trial completion • Trial completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • NRAS mutation
    |
    LNP3794
    over2years
    A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS]) (clinicaltrials.gov)
    P1, N=8, Terminated, Boehringer Ingelheim | N=124 --> 8 | Trial completion date: Jul 2024 --> Apr 2022 | Suspended --> Terminated | Trial primary completion date: Oct 2023 --> Apr 2022; Sponsor decision
    Preclinical • Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12 • KRAS G13 • KRAS A146 • KRAS Q61 • KRAS A59 • KRAS K117 • KRAS exon 4 mutation
    |
    LNP3794 • BI 1701963
    over2years
    A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive) (clinicaltrials.gov)
    P1, N=12, Recruiting, Boehringer Ingelheim | Active, not recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • NRAS mutation
    |
    LNP3794
    over2years
    A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS]) (clinicaltrials.gov)
    P1, N=124, Suspended, Boehringer Ingelheim | Recruiting --> Suspended
    Preclinical • Trial suspension • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12 • KRAS G13 • KRAS A146 • KRAS Q61 • KRAS A59 • KRAS K117 • KRAS exon 4 mutation
    |
    LNP3794 • BI 1701963
    almost3years
    A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive) (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • NRAS mutation
    |
    LNP3794
    almost3years
    A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, Lupin Ltd.
    Clinical • New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • NRAS mutation
    |
    LNP3794
    3years
    A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive) (clinicaltrials.gov)
    P1, N=12, Recruiting, Boehringer Ingelheim | Trial primary completion date: Nov 2021 --> Mar 2022
    Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • NRAS mutation
    |
    LNP3794
    over3years
    A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS]) (clinicaltrials.gov)
    P1, N=124, Recruiting, Boehringer Ingelheim | Trial completion date: Sep 2023 --> Jul 2024 | Trial primary completion date: Nov 2022 --> Oct 2023
    Clinical • Preclinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12 • KRAS G13 • KRAS A146 • KRAS Q61 • KRAS A59 • KRAS K117 • KRAS exon 4 mutation
    |
    LNP3794 • BI 1701963
    over3years
    A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS]) (clinicaltrials.gov)
    P1, N=124, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Preclinical • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12 • KRAS G13 • KRAS A146 • KRAS Q61 • KRAS A59 • KRAS K117 • KRAS exon 4 mutation
    |
    LNP3794 • BI 1701963
    over3years
    A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS]) (clinicaltrials.gov)
    P1, N=124, Not yet recruiting, Boehringer Ingelheim
    Clinical • New P1 trial • Preclinical • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12 • KRAS G13 • KRAS A146 • KRAS Q61 • KRAS A59 • KRAS K117 • KRAS exon 4 mutation
    |
    LNP3794 • BI 1701963
    over3years
    A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive) (clinicaltrials.gov)
    P1, N=12, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • NRAS mutation
    |
    LNP3794
    almost4years
    [VIRTUAL] Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan. (AACR 2021)
    Here, we present pre-clinical data showing enhanced pathway modulation and synergistic anti-tumor effects following vertical pathway inhibition of BI 1701963 in combination with mitogen-activated protein kinase inhibitors (MEKi; trametinib and BI 3011441) or KRAS G12C inhibitors (MRTX849 and BI 1823911). Primary endpoints include dose-limiting toxicities, treatment-emergent or -related adverse events. Secondary endpoints include pharmacokinetic and pharmacodynamic properties of combination regimens and preliminary efficacy.
    P1 data • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase) • SOS1 (SOS Ras/Rac Guanine Nucleotide Exchange Factor 1)
    |
    KRAS mutation • KRAS G12D • KRAS G13
    |
    Mekinist (trametinib) • irinotecan • Krazati (adagrasib) • LNP3794 • BI 1823911 • BI 1701963
    almost4years
    A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive) (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Boehringer Ingelheim
    Clinical • New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • NRAS mutation
    |
    LNP3794